Clinical Trial Update: A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating orelabrutinib for refractory immune thrombocytopenia (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia, Bruton's Tyrosine Kinase | Phase 2 | Status: UNKNOWN